Crinetics Pharmaceuticals (CRNX) Total Liabilities (2017 - 2026)

Crinetics Pharmaceuticals has reported Total Liabilities for 10 years, with the latest figure at $120.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 12.44% year-over-year to $120.7 million; the trailing twelve-month figure through Mar 2026 stood at $120.7 million (up 12.44% YoY), and the FY2025 full-year result was $134.2 million, up 22.21% from the prior year.
• Total Liabilities for Q1 2026 stood at $120.7 million, down from $134.2 million in the prior quarter.
• The five-year high for Total Liabilities was $134.2 million in Q4 2025, with the low at $30.2 million in Q1 2022.
• Average Total Liabilities over 5 years is $83.8 million, with a median of $103.2 million recorded in 2024.
• Year-over-year, Total Liabilities jumped 206.48% in 2024 and rose 3.98% in 2025.
• Tracing CRNX's Total Liabilities over 5 years: stood at $35.8 million in 2022, then jumped by 168.49% to $96.2 million in 2023, then increased by 14.07% to $109.8 million in 2024, then climbed by 22.21% to $134.2 million in 2025, then declined by 10.06% to $120.7 million in 2026.
• The last three Total Liabilities figures came in at $120.7 million (Q1 2026), $134.2 million (Q4 2025), and $123.9 million (Q3 2025), per Business Quant data.

Peer Comparison